Trump Administration Plans New Tariffs on Drugmakers Without Price Agreements
Trump administration readies new tariffs on select drugmakers: Report
The Economic Times
Image: The Economic Times
The Trump administration is preparing to announce tariffs on drugmakers that fail to secure low-price agreements in the U.S. A potential 100% tariff on imported branded medicines could impact companies not negotiating with the administration, while Pfizer and AstraZeneca have already secured exemptions.
- 01The Trump administration may impose a 100% tariff on certain imported medicines.
- 02Drugmakers without pricing agreements will face significant penalties.
- 03Pfizer and AstraZeneca have secured multi-year exemptions.
- 04Eli Lilly, Johnson & Johnson, and Merck are investing in U.S. operations to avoid tariffs.
- 05Plans are still subject to change, with possible exemptions for some medicines.
Advertisement
In-Article Ad
The Trump administration is reportedly set to announce tariffs on drugmakers that have not established agreements to provide low prices in the United States. According to Bloomberg News, this could include a 100% tariff on imported branded and patented medicines. Companies like Pfizer and AstraZeneca have already secured multi-year exemptions by entering pricing agreements, while others such as Eli Lilly, Johnson & Johnson, and Merck are investing billions to expand their U.S. operations to avoid potential penalties. The administration's plans are not yet finalized and may still change, with the possibility of exemptions for certain medicines and disease categories.
Advertisement
In-Article Ad
This could lead to higher drug prices for consumers in the U.S. if tariffs are implemented, as companies may pass on costs to customers.
Advertisement
In-Article Ad
Read the original article
Visit the source for the complete story.